Keyphrases
Human Epidermal Growth Factor Receptor 2 (HER2)
100%
Targeted Therapy
100%
Advanced Breast Cancer
100%
Redrawing
100%
Phase II Trial
55%
Direct Therapy
33%
Trastuzumab Deruxtecan (T-DXd)
33%
Overall Survival
22%
Median Progression-free Survival
22%
Trastuzumab
22%
Capecitabine
22%
Tucatinib
22%
Hazard Ratio
11%
Breast Cancer
11%
Overall Response Rate
11%
Clinical Benefit
11%
Efficacy Outcomes
11%
Duration of Response
11%
Median Overall Survival
11%
Randomized Phase II Trial
11%
Search Terms
11%
Response-outcome
11%
Clinical Reports
11%
Brain Metastases
11%
Second-line Therapy
11%
Targeted Agents
11%
Poziotinib
11%
T-DM1
11%
Margetuximab
11%
Beyond Progression
11%
Heavily Pretreated Patients
11%
Human Epidermal Growth Factor Receptor 2-positive Breast Cancer
11%
Zenocutuzumab
11%
Third-line Therapy
11%
Neratinib
11%
Medicine and Dentistry
Breast Cancer
100%
Targeted Therapy
100%
Epidermal Growth Factor Receptor 2
100%
Gamma Urogastrone
100%
Overall Survival
33%
Phase II Trials
33%
Trastuzumab Deruxtecan
33%
Phase III Trials
33%
Progression Free Survival
22%
Trastuzumab
22%
Capecitabine
22%
Tucatinib
22%
Hazard Ratio
11%
Clinical Trial
11%
Brain Metastasis
11%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
11%
Zenocutuzumab
11%
Poziotinib
11%
Neratinib
11%
Margetuximab
11%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Epidermal Growth Factor Receptor 2
100%
Gamma Urogastrone
100%
Overall Survival
33%
Phase II Trials
33%
Trastuzumab Deruxtecan
33%
Phase III Trials
33%
Progression Free Survival
22%
Trastuzumab
22%
Capecitabine
22%
Tucatinib
22%
Clinical Trial
11%
Brain Metastasis
11%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
11%
Zenocutuzumab
11%
Poziotinib
11%
Margetuximab
11%
Neratinib
11%
Biochemistry, Genetics and Molecular Biology